What are the functions and effects of Ensifentrine?

Ohtuvayre (Ensifentrine)-Ensifentine Inhalation Suspension is a new dual-action drug primarily used to treat chronic obstructive pulmonary disease (COPD) and other respiratory diseases. As an innovative drug, exefantine not only has a bronchodilatory effect but also reduces airway inflammatory response by acting on two key biological pathways at the same time. This makes it show significant potential in alleviating the symptoms of COPD and other diseases and improving lung function.

Chronic obstructive pulmonary disease (COPD) is a common respiratory disease, usually caused by factors such as long-term smoking or air pollution. It is characterized by symptoms such as chronic inflammation of the airways and lungs, airflow restriction, and difficulty breathing. COPD patients often face long-term respiratory symptoms such as coughing, wheezing, and shortness of breath, which seriously affect the patient's quality of life. Traditional treatments for COPD include bronchodilators and anti-inflammatory drugs, but these treatments often only relieve symptoms and have limited therapeutic effect.

Exefentine is unique in its dual mechanism of action. First, it inhibits two enzymes, namely cyclic adenosine monophosphate (cAMP) degrading enzyme and 5-phosphodiesterase, thereby reducing the production of a variety of pro-inflammatory factors and reducing airway inflammatory response. Since airway inflammation is a key pathological feature of diseases such as COPD, exefentine helps improve patients' symptoms by inhibiting the inflammatory response and reduces the risk of acute exacerbations of the disease and worsening of symptoms.

Secondly, another important effect of exefantine is bronchodilation. It can relax airway smooth muscles, expand airways, improve airflow restriction, and enhance airway patency. This is particularly important for COPD patients, because one of the core symptoms of COPD is airway obstruction, leading to difficulty breathing. By dilating the airways, exefentine helps relieve patients' symptoms such as shortness of breath and shortness of breath, and improves patients' quality of daily life.

The dual mechanism of exefantine gives it more advantages than traditional single-acting drugs. Traditional bronchodilators, such as short-acting or long-acting beta2 receptor agonists, dilate the airways mainly by relaxing airway smooth muscles, but they usually have limited inhibitory effects on the inflammatory response. Traditional anti-inflammatory drugs, such as inhaled steroids, improve symptoms primarily by reducing airway inflammation, but their direct dilation effect on the airways is weak. Therefore, the dual effects of exefantine make it have obvious advantages in controlling COPD symptoms, improving lung function, and delaying disease progression.

In addition, exefantine is being studied for the treatment of other types of respiratory diseases, such as asthma. Asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness and reversible airflow limitation, often accompanied by symptoms such as wheezing, coughing and dyspnea. Unlike COPD, airway inflammation in asthma is often closely related to allergic reactions. By reducing airway inflammation and dilating the airways, exefantine may help relieve symptoms in asthma patients, especially in patients whose symptoms cannot be fully controlled by medications, providing a new treatment option.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html